vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 7.5%, a 58.3% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 14.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 8.1%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
SCYX vs SIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $24.0M |
| Net Profit | $12.3M | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | 56.3% | 10.7% |
| Net Margin | 65.7% | 7.5% |
| Revenue YoY | 1808.5% | 14.8% |
| Net Profit YoY | 376.5% | 177.3% |
| EPS (diluted) | $0.25 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $24.0M | ||
| Q3 25 | $334.0K | $22.8M | ||
| Q2 25 | $1.4M | $22.1M | ||
| Q1 25 | $257.0K | $19.0M | ||
| Q4 24 | $977.0K | $20.9M | ||
| Q3 24 | $660.0K | $21.7M | ||
| Q2 24 | $736.0K | $22.0M | ||
| Q1 24 | $1.4M | $20.5M |
| Q4 25 | $12.3M | $1.8M | ||
| Q3 25 | $-8.6M | $-429.0K | ||
| Q2 25 | $-6.9M | $3.4M | ||
| Q1 25 | $-5.4M | $-1.4M | ||
| Q4 24 | — | $-2.3M | ||
| Q3 24 | $-2.8M | $-443.0K | ||
| Q2 24 | $-14.5M | $72.0K | ||
| Q1 24 | $411.0K | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | 56.3% | 10.7% | ||
| Q3 25 | -2516.5% | -1.7% | ||
| Q2 25 | -701.0% | 14.8% | ||
| Q1 25 | -3350.2% | -4.1% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | -1563.6% | -1.5% | ||
| Q2 24 | -1255.0% | 0.7% | ||
| Q1 24 | -692.5% | -6.5% |
| Q4 25 | 65.7% | 7.5% | ||
| Q3 25 | -2572.2% | -1.9% | ||
| Q2 25 | -504.8% | 15.4% | ||
| Q1 25 | -2097.7% | -7.3% | ||
| Q4 24 | — | -11.1% | ||
| Q3 24 | -425.5% | -2.0% | ||
| Q2 24 | -1964.4% | 0.3% | ||
| Q1 24 | 29.9% | -7.8% |
| Q4 25 | $0.25 | $0.29 | ||
| Q3 25 | $-0.17 | $-0.07 | ||
| Q2 25 | $-0.14 | $0.56 | ||
| Q1 25 | $-0.11 | $-0.23 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | $-0.06 | $-0.07 | ||
| Q2 24 | $-0.30 | $0.01 | ||
| Q1 24 | $0.01 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $1.1M |
| Total DebtLower is stronger | — | $39.0K |
| Stockholders' EquityBook value | $49.4M | $38.7M |
| Total Assets | $59.0M | $74.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $1.1M | ||
| Q3 25 | $37.9M | $491.0K | ||
| Q2 25 | $44.8M | $2.0M | ||
| Q1 25 | $40.6M | $1.9M | ||
| Q4 24 | $59.3M | $3.1M | ||
| Q3 24 | $68.8M | $1.7M | ||
| Q2 24 | $73.0M | $3.4M | ||
| Q1 24 | $80.2M | $2.5M |
| Q4 25 | — | $39.0K | ||
| Q3 25 | — | $51.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | $49.4M | $38.7M | ||
| Q3 25 | $36.4M | $36.9M | ||
| Q2 25 | $44.5M | $35.8M | ||
| Q1 25 | $50.5M | $32.4M | ||
| Q4 24 | $55.1M | $33.7M | ||
| Q3 24 | $58.5M | $30.4M | ||
| Q2 24 | $60.4M | $29.8M | ||
| Q1 24 | $74.1M | $29.7M |
| Q4 25 | $59.0M | $74.9M | ||
| Q3 25 | $51.1M | $73.4M | ||
| Q2 25 | $60.7M | $77.3M | ||
| Q1 25 | $67.9M | $78.8M | ||
| Q4 24 | $90.6M | $81.0M | ||
| Q3 24 | $99.0M | $104.6M | ||
| Q2 24 | $107.8M | $106.3M | ||
| Q1 24 | $118.3M | $104.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $8.1M |
| Free Cash FlowOCF − Capex | — | $8.0M |
| FCF MarginFCF / Revenue | — | 33.3% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | 1.50× | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $8.1M | ||
| Q3 25 | $-8.7M | $726.0K | ||
| Q2 25 | $-7.5M | $371.0K | ||
| Q1 25 | $-7.5M | $2.8M | ||
| Q4 24 | $-24.0M | $-3.8M | ||
| Q3 24 | $765.0K | $857.0K | ||
| Q2 24 | $-10.9M | $382.0K | ||
| Q1 24 | $-4.0M | $-3.2M |
| Q4 25 | — | $8.0M | ||
| Q3 25 | — | $566.0K | ||
| Q2 25 | — | $310.0K | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $580.0K | ||
| Q2 24 | — | $-175.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 14.1% | ||
| Q4 24 | — | -18.8% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | -18.9% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | 1.50× | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
